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Although most components of the mitochondrial translation apparatus are encoded by
nuclear genes, all known molecular defects associated with impaired mitochondrial
translation are due to mutations in mitochondrial DNA. We investigated two siblings
with a severe defect in mitochondrial translation, reduced levels of oxidative phosphory-
lation complexes containing mitochondrial DNA (mtDNA)–encoded subunits, and pro-
gressive hepatoencephalopathy. We mapped the defective gene to a region on chromo-
some 3q containing elongation factor G1 (EFG1), which encodes a mitochondrial
translation factor. Sequencing of 
 
EFG1
 
 revealed a mutation affecting a conserved residue
of the guanosine triphosphate (GTP)–binding domain. These results define a new
 
class of gene defects underlying disorders of oxidative phosphorylation.
 
xidative phosphorylation drives the synthesis of atp and
 
takes place through a series of reactions mediated by complexes I, II, III, IV,
and V, which are integral to the inner mitochondrial membrane. Each com-
plex is made up of several or many proteins.
 
1,2
 
 For example, complex I is made up of
7 proteins encoded by mitochondrial genes and at least 39 proteins encoded by nuclear
genes. Some diseases result from a deficit in a single complex. For example, Leigh’s
syndrome is caused by a single mutation in one of several mitochondrial and nuclear
genes encoding proteins that make up, assemble, or maintain complex I, II, IV, or V. The
cause of diseases associated with a deficit in more than one complex and of nuclear
origin has been unclear, and the prevalence of such mitochondrial disorders is similar
to that of the aggregate of disorders caused by the deficiency of a single complex. In
this report, we describe an association between the mutation of a nuclear gene encod-
ing a protein that mediates translation of mitochondrial DNA (mtDNA) and the occur-
rence of early fatal hepatoencephalopathy in two siblings, each with a deficit in more
than one complex of the respiratory chain.
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The index patient, a female, was born of consan-
guineous Lebanese parents (first cousins) by cesar-
ean section with intrauterine growth retardation
and mild microcephaly. She was very stiff and had
few spontaneous movements. From day 10 of life,
profound metabolic acidosis was evident (blood lac-
tate level, 17.1 mmol per liter [normal, <2.1 mmol
per liter]; lactate:pyruvate ratio, 38 [normal, 12 to
18]). Liver dysfunction, as measured by an elevation
of direct bilirubin, was observed from day 7 and
progressed to full liver failure on day 12 and death
on day 27. Postmortem examination of the liver
showed cholestasis and extensive necrosis. There
was hypoplasia of the corpus callosum, and several
symmetrical cystic lesions were present in the white
matter in the area of the basal ganglia. The heart
was normal, and a histologic examination of the
skeletal muscle showed normal mitochondrial mor-
phology and no ragged-red fibers. The activities of
the oxidative phosphorylation complexes in fibro-
blasts were 40 percent, 69 percent, and 18 percent
of the lowest control value for complex I, complex
III, and complex IV, respectively. In muscle, com-
plex I activity was 52 percent and complex IV activ-
ity was 54 percent of the lowest control value.
A male sibling of the index patient was born at
41 weeks of gestation. The maximal blood lactate
level was 9.3 mmol per liter, with a lactate:pyruvate
ratio of 84. An ultrasonographic examination of
the brain showed generalized atrophy and a small
corpus callosum. The child had extremely delayed
growth and development, as well as increased mus-
cle tone in his upper extremities. Signs of liver fail-
ure were present at week 7, leading to death at five
months of age. The heart was normal. The activi-
ties of complex I and complex IV in fibroblasts
were 13 percent and 31 percent of the lowest con-
trol value, respectively. Analysis of mtDNA by South-
ern blotting showed no rearrangements or reduc-
tion in mtDNA levels.
 
controls
 
Samples from 100 ethnically matched controls were
analyzed for restriction-fragment–length polymor-
phisms and showed a pattern that was homozy-
gous for the wild-type allele.
 
cell culture
 
To extend the life span of cells, we immortalized
primary human skin fibroblasts with a retrovirus
containing the 
 
E6
 
 and 
 
E7
 
 genes of human papillo-
mavirus type 16, or with 
 
E7
 
 alone and a retroviral
vector expressing the protein component of hu-
man telomerase reverse transcriptase.
 
3
 
 Skin fibro-
blasts from the siblings and controls were cultured
in Dulbecco’s modified Eagle medium supplement-
ed with 10 percent fetal-calf serum, penicillin, and
streptomycin. Samples were collected after informed
consent was given.
 
enzyme measurements
 
Complex I, complex III, complex IV, and citrate syn-
thase activities were measured in fibroblast-cell
extracts as described previously.
 
4,5
 
 The rho
 
0
 
 test was
performed, whereby 143B.TK
 
¡
 
 rho
 
0
 
 cells (cells with-
out mtDNA that were derived from 143B.TK
 
¡
 
 cells)
were fused with enucleated skin fibroblasts from
the index patient and then selected in Dulbecco’s
modified Eagle medium containing 10 percent
fetal-calf serum without pyruvate or uridine. Col-
onies were harvested for immunoblot analysis.
 
chromosome transfer
 
The E6-and-E7–immortalized fibroblasts from the
siblings were fused with human chromosomes iso-
lated by microcell-mediated chromosome trans-
fer
 
4,6
 
 from a panel of mouse cell lines containing
one extra human chromosome with a hygromycin-
resistant tag.
 
7
 
microsatellite mapping
 
The short tandem-repeat microsatellite markers
used for homozygosity and deletion mapping of
chromosome 3 after chromosome transfer were
derived from the Applied Biosystems ABI PRISM
Linkage Mapping Set (version 2.5 MD-10). The in-
termarker distance was about 10 cM.
 
c
 
dna sequencing
 
RNA was isolated from skin fibroblasts from the
siblings and controls with the use of RNAzol.
Primers were designed for the amplification of com-
plementary DNA (cDNA) from 
 
MRPS22
 
 and 
 
EFG1
 
.
The polymerase-chain-reaction (PCR) fragments
were used for direct sequencing with the ABI
PRISM 377 DNA Sequencer (Applied Biosystems).
case reports
methods
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analysis of restriction-fragment–length 
polymorphisms
 
Genomic DNA was isolated from skin fibroblasts
from the index patient and from blood of the par-
ents, the sibling, and 100 controls. The DNA was
amplified and digested with the restriction en-
zyme 
 
Mse
 
I.
 
blue-native polyacrylamide-gel 
electrophoresis and immunoblotting
 
Blue-native polyacrylamide-gel electrophoresis
 
8
 
was used for separation of oxidative phosphoryla-
tion complexes on 5 percent to 15 percent poly-
acrylamide-gradient gels. Mitoplasts, which were
prepared from fibroblasts by treatment with 0.8 mg
of digitonin per milligram of protein, were solubi-
lized with 1 percent lauryl maltoside, and 10 to 20 µg
of the solubilized protein was used for electropho-
resis. Complexes I through V were detected by im-
munoblot analysis with the use of monoclonal
antibodies against complex III core protein 1, the
 
a
 
 subunit of complex V, the 70-kD subunit of com-
plex II (Molecular Probes), monoclonal antibodies
against complex IV subunit IV, and a polyclonal
anti-ND1 antibody (an antibody acting against the
mitochondrial-encoded ND1 subunit of complex I).
For immunoblotting, fibroblasts were solubilized
with 1.5 percent lauryl maltoside in phosphate-
buffered saline, and 30 
 
µ
 
g of protein was separated
by TRIS-Tricine sodium dodecyl sulfate–polya-
crylamide-gel electrophoresis. The proteins were
transferred to nitrocellulose, and antibodies direct-
ed against complex IV subunits II and IV and com-
plex III core protein 2 were used for detection.
 
pulse-labeling of mitochondrial 
translation products
 
In vitro labeling of mitochondrial translation was
performed as previously described.
 
9
 
 Briefly, cells
were labeled for 60 minutes at 37°C in methionine-
free Dulbecco’s modified Eagle medium contain-
ing 200 µCi per milliliter of [35S]methionine and
100 µg per milliliter of emetine followed by 10 min-
utes in regular Dulbecco’s modified Eagle medium.
Total cellular protein (50 
 
µ
 
g) was resuspended in
loading buffer containing 93 mM TRIS-hydrogen
chloride (pH 6.7), 7.5 percent glycerol, 3.5 percent
sodium dodecyl sulfate, 0.25 mg bromophenol blue
per milliliter, and 3 percent mercaptoethanol, was
sonicated for 3 to 8 seconds, and was loaded and
run on 12 percent to 20 percent polyacrylamide-
gradient gels.
 
c
 
dna constructs
 
Retroviral vectors containing the cDNA sequence of
three mitochondrial translation factors (
 
EFG1, EFG2,
 
and 
 
IF3
 
) were created with the Gateway cloning sys-
tem (Invitrogen). We used the reverse-transcriptase
PCR (OneStep RT-PCR kit, Qiagen) to amplify cDNA
from 
 
EFG2
 
 and 
 
IF3
 
 genes with the use of specific
primers modified for cloning into Gateway vectors.
The cDNA from 
 
EFG1
 
 was amplified from IMAGE
(Integrated Molecular Analysis of Genomes and
Their Expression) clone 5574223 with use of specif-
ic primers modified for cloning into Gateway vec-
tors. The PCR constructs were cloned into a Gate-
way-modified retroviral-expression vector, pLXSH.
The fidelity of the cDNA clones was confirmed by
automated DNA sequencing.
 
infection with viruses
 
Virus-producing cell lines were generated accord-
ing to procedures described previously.
 
10
 
 Briefly, a
human 293-derived retroviral packaging cell line
(293GPG) was transfected with a retroviral con-
struct containing one of the mitochondrial trans-
lation factors. Tetracycline was removed from the
medium two days after transfection to induce virus
production. Fibroblasts from the index patient and
the controls were infected 72 to 96 hours later by
exposure to virus-containing medium in the pres-
ence of 4 µg per milliliter of polybrene as previ-
ously described.
 
3
 
genbank accession numbers
 
The GenBank accession numbers for 
 
EFG1, EFG2,
IF3,
 
 and 
 
MRPS22
 
 are NM_024996, NM_032380,
AF410851, and NM_020191, respectively.
Fibroblasts from the index patient showed low
levels of fully assembled complexes I, III, IV, and V
but normal levels of complex II (Fig. 1). To deter-
mine whether this assembly defect was of nuclear
or mitochondrial origin, we prepared transmito-
chondrial cytoplasmic hybrid (cybrid) cells by fus-
ing enucleated fibroblasts from the index patient
with rho
 
0
 
 cells, which are devoid of mtDNA but
contain a normal nuclear genome. We observed
normal steady-state levels of complex IV subunit II,
as well as complex III core protein 2 and complex IV
subunit IV in the cybrid cells (data not shown), con-
firming that the oxidative phosphorylation deficien-
cy was recessive and of nuclear origin.
results
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To map the defective gene, we used microcell-
mediated chromosome transfer to identify a normal
human chromosome that could functionally com-
plement the biochemical defect in the fibroblasts
from the index patient.
 
4,6
 
 We transferred all human
autosomes and the X chromosome, one at a time,
into an immortalized fibroblast line from the pa-
tient and used immunoblot analysis of complex IV
subunit II as an assay for complementation. The
protein levels of complex IV subunit II were re-
stored only after the transfer of chromosome 3 (in
18 of 19 clones; data not shown).
Chromosomes incorporated into the genome of
recipient cells by microcell-mediated chromosome
transfer often undergo rearrangements and dele-
tions. Deletion mapping of the donor chromosome
in isolated clones can thus be used for fine map-
ping of the genomic region containing the comple-
menting gene. Microsatellite mapping with a panel
of polymorphic markers for chromosome 3 showed
that one of the complementing clones contained
only marker D3S1279, and that the fibroblast line
from the patient was homozygous for markers
D3S1279 and D3S1285. These data suggested that
the candidate gene maps to the region located about
20 cM from marker D3S1279 at 3q22–26.2 and
flanked by markers D3S1569 and D3S1614.
A database search for candidate genes in this re-
gion identified two genes, 
 
EFG1
 
 and 
 
MRPS22,
 
 that
code for proteins that are part of the mitochondrial
translation machinery.
 
11,12
 
 Sequence analysis of
cDNA showed a homozygous mutation (A521G) in
the 
 
EFG1
 
 cDNA isolated from the patient’s immor-
 
Figure 1. Analysis of Fibroblasts from the Index Patient.
 
Fibroblasts from the index patient and a control were 
analyzed with the use of blue-native polyacrylamide-gel 
electrophoresis after transduction with retroviral con-
structs expressing mitochondrial translation factors. 
The gels were immunoblotted to assess the amount of 
fully assembled oxidative phosphorylation complexes. 
The expression of EFG1 partially rescues the assembly 
defect in the patient’s cells.
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Figure 2. Analysis of 
 
EFG1
 
.
 
Sequence analysis of the complementary DNA of 
 
EFG1
 
 
(Panel A) shows a homozygous A521G mutation in the 
patient as compared with the control. A schematic repre-
sentation (Panel B) of the EFG1 protein shows the GTP-
binding elongation-factor signature sequence (black 
box) and the GTP-binding domain, consisting of three 
consensus-sequence elements with distinct spacing 
(white boxes). The consensus-sequence element NKXD 
is part of the GTP-binding domain and is responsible for 
base specificity. The consensus sequence of the GTP-
binding domain is conserved across many functionally 
different families of GTP-binding proteins. The figure 
shows the absolute conservation of the sequence of as-
paragine at position 174 of the third consensus element 
in EFG1 factor among taxa as far back as prokaryotes. 
Agarose gel was used in the analysis of the restriction-
fragment–length polymorphisms that confirmed the 
mutation (Panel C). A polymerase-chain-reaction frag-
ment of 
 
EFG1
 
 encompassing the mutation was ampli-
fied from genomic DNA. The mutation eliminates an 
 
Mse
 
I restriction-enzyme site. Results from the patient, 
father, mother, sibling, and control are shown.
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talized fibroblasts (Fig. 2A), which predicts an
amino acid substitution of serine for asparagine
(N174S) at a position that has been absolutely con-
served during evolution (Fig. 2B). The presence of
the mutation was confirmed in genomic DNA from
the index patient and the sibling by analysis of
restriction-fragment–length polymorphisms (Fig.
2C). The same analysis showed that both parents
were heterozygous for the mutation. The mutation
could not be detected in genomic DNA of 100 con-
trols of Lebanese origin who were found to be ho-
mozygous for the wild-type allele by analysis of
restriction-fragment–length polymorphisms. The
index patient’s cDNA sequence of 
 
MRPS22
 
 was
normal.
Pulse labeling of the mitochondrial translation
products with [
 
35
 
S]methionine showed a decrease
in overall mitochondrial translation to about 20 per-
cent of the overall translation in the controls. The
deficit in translation varied from protein to pro-
tein. For instance, the expression of complex IV
subunits I, II, and III was reduced to about 15 per-
cent of the expression of the complex IV subunits
in the controls, and expression of ND5 and ND6
to about 10 percent of control equivalents, whereas
the other ND subunits were less affected (30 to 60
percent of control equivalents). Overexpression of
EFG1 cDNA in fibroblasts from the index patient
increased the overall mitochondrial translation to
about 40 percent of the expression observed in the
controls (Fig. 3); overexpression of two other mito-
chondrial translation factors (
 
EFG2
 
 or 
 
IF3
 
) had no
effect on mitochondrial translation.
Rescue of mitochondrial translation in fibro-
blasts from the index patient was accompanied by
a rescue of complex IV activity from 20 percent of
the activity in the controls to 72 percent. Further-
more, we observed an increase in the amount of
fully assembled complexes I, III, IV, and V (Fig. 1).
Overexpression of EFG2 slightly increased the
amount of fully assembled complexes I, III, and V
but did not result in a substantial increase in com-
plex IV activity.
Synthesis of mitochondrial proteins requires a
number of initiation, elongation, and termination
(or release) factors, all of which are encoded by
nuclear genes. The cDNA for two initiation fac-
tors (IF2, IF3),
 
13,14
 
 four elongation factors (EFTu,
 
15
 
EFTs,
 
16
 
 EFG1,
 
17
 
 and EFG2
 
3
 
), and a release factor
(RF1)
 
18
 
 have been cloned and sequenced in human
and other mammalian species. IF2 promotes the
binding of formyl methionyl–transfer RNA (fMet–
tRNA) to the small ribosomal subunit in the pres-
ence of GTP and a template,
 
19
 
 whereas IF3 promotes
the dissociation of the two ribosomal subunits,
which produces free small subunits for the initia-
tion of translation.
 
14
 
 The mammalian elongation
factor Tu participates in the formation of the terna-
ry complex that includes EFTu, GTP, and amino-
acyl–tRNA, which delivers the aminoacyl–tRNA to
the acceptor site of the ribosome.
 
20
 
 The energy re-
quired for this process is supplied by the hydroly-
sis of GTP, which is followed by the release of EFTu
from the ribosome as an EFTu–guanosine diphos-
phate (GDP) complex. The exchange of GDP for
GTP, which regenerates EFTu–GTP, is accomplished
by EFTs.
 
20
 
 
Although the roles of the mammalian elonga-
tion factors G1 and G2 have not been studied, elon-
gation factor G in prokaryotes hydrolyzes GTP
 
21
discussion
 
Figure 3. Analysis of Mitochondrial Translation Products.
 
Fibroblasts from the index patient that were overexpressing the mitochondri-
al translation factors EFG1, EFG2, and IF3 were pulse-labeled with [
 
35
 
S]methi-
onine in the presence of an inhibitor of cytoplasmic protein synthesis 
(emetine) to assess the rate of mitochondrial translation. The patient’s fibro-
blasts showed a severe defect in mitochondrial translation that overexpres-
sion of EFG1, as shown by Northern blotting, partially rectified (to about 40 
percent of the expression observed in the controls) but that overexpression of 
the other translation factors did not affect. The proteins include seven sub-
units of complex I (ND), three subunits of complex IV (CO), the cytochrome 
 
b
 
 subunit of complex III (cyt 
 
b
 
), and two subunits of adenosine triphosphate 
(ATP) synthase (ATPase 6 and ATPase 8).
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and, in so doing, catalyzes the translocation of
peptidyl–tRNA from the ribosomal-acceptor site
to the peptidyl site after peptide-bond formation.
Concomitant movement of mRNA exposes the next
codon in the acceptor site.
 
22
 
 RF1 recognizes stop
codons and promotes the release of the completed
protein chain.
It is not clear why there are two mammalian ho-
mologues of the prokaryotic elongation factor G.
Perhaps each catalyzes translation from a specific
set of mRNA, or perhaps they are redundant, to en-
sure survival when one fails. Studies of yeast lend
support to the latter hypothesis; deletion mutations
of either 
 
EFG1
 
 or 
 
EFG2
 
 are viable, although 
 
EFG1
 
 mu-
tations have a phenotype of respiratory deficiency.
 
23
 
Our observations suggest that 
 
EFG1
 
 is an essential
gene and that EFG1 and EFG2 have different but
overlapping roles in mitochondrial translation
(Fig. 1). Although the expression of both proteins
is ubiquitous,
 
11,17
 
 the proteins may have tissue-
specific functions, consistent with the severe effect
of mutant EFG1 in the liver and brain and the mild
effect in the heart and muscles.
Many GTP-binding proteins contain three high-
ly conserved consensus elements (Fig. 2B).
 
24
 
 The
A521G mutation effects the substitution of a high-
ly conserved asparagine residue present in the
consensus-sequence element NKXD (where X in-
dicates any amino acid), which is part of the GTP-
binding domain and is responsible for base speci-
ficity.
 
24
 
 A mutant variant of another GTP-binding
protein, Ras p21, with replacement of the equiva-
lent asparagine by lysine or tyrosine, is unable to
bind guanine nucleotides or to transform NIH 3T3
cells.
 
25
 
 The mutant residue in EFG1 may also blunt
GTP-binding activity, with consequent loss of effi-
ciency of mitochondrial translation.
We report a mutation affecting a nuclear-encod-
ed component of the mitochondrial translation
system in an oxidative phosphorylation disorder.
Patients with combined deficiencies of oxidative
phosphorylation enzymes are at least as common
as those with isolated deficiencies of single-enzyme
complexes. Nuclear genes encoding the mitochon-
drial translation factors are good candidates as
causative genes in these cases.
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